GYNIM is a specialist medical practice in Mechelen. Private Limited, started on 30 March 1993, 1 establishment.

What is the address of GYNIM?

The registered office of GYNIM is located at Schuttersvest 47, 2800 Mechelen.

Is GYNIM still active?

Yes. According to the CBE (30 October 2026) GYNIM is active, legal situation “Normale toestand”, started on 30 March 1993.

Is GYNIM registered on Peppol?

Yes, GYNIM is registered on the Peppol network with ID 0208:0449783951.

What is the enterprise number of GYNIM?

The enterprise number of GYNIM is BE0449783951.

When was GYNIM founded?

GYNIM was founded on 30 March 1993.

Is GYNIM a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 30 March 1993; 5 annual accounts filed, latest fiscal year 2025; 8 directors known from the annual account.

How much profit did GYNIM make in 2025?

GYNIM posted a profit after taxes of € 2,685 in financial year 2025.

What is the revenue of GYNIM?

As a small company, GYNIM is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 100,943.

How many employees does GYNIM have?

According to the 2025 annual accounts, GYNIM has 0 full-time equivalents (FTE).

GYNIM (Private Limited) - Mechelen - BE0449783951

Q: Who are the directors of GYNIM?

According to the 2025 annual accounts, the directors of GYNIM are: Dr. Sofie Pelckmans BV, Dr Jan Bosteels BV, Dr. Ine Tavano BV, Dr Nele Roggen BV, Dokter Els Lannoey BV, Dr Stefanie Verhelst BV, Dokter Jan Baekelandt BV, Dokter Lynn Vercammen gynaec BV.

Dossier GYNIM, printed on 30 October 2026 from databakkes.be/en/0449783951/gynim. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 18 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

GYNIM from Mechelen, company number BE0449783951, closed financial year 2025 with a result of € 2,685 after tax. For that financial year GYNIM recorded a gross margin of € 100,943 and equity of € 99,345. Compared with financial year 2024, the result moved from € 3,858 to € 2,685. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 30, 2026.

What it is worth Growing

€ 99,345

▲ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 2,685

▼ 30% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 12,512

▲ € 10,718 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 62,161.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Vehicles and equipment

€ 31,464

▼ 17% vs 2024

Of which on lease € 23,804.

Debts at end 2025

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 162,144

▼ 33% vs 2024

€ 27,834 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 10,588

▼ 46% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 16

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 504,243 Gross margin 2022: € 504,243 First fiscal year in the series	€ 317,254 Gross margin 2023: € 317,254 ▼ 37% vs 2022 (€ 504,243) Unfavourable step	€ 433,506 Gross margin 2024: € 433,506 ▲ 37% vs 2023 (€ 317,254) Favourable step	€ 100,943 Gross margin 2025: € 100,943 ▼ 77% vs 2024 (€ 433,506) Unfavourable step	▼ 77%
Profit after taxes	€ 0 Profit after taxes 2022: € 0 First fiscal year in the series	€ 3,401 Profit after taxes 2023: € 3,401 Unchanged (€ 0) Favourable step	€ 3,858 Profit after taxes 2024: € 3,858 ▲ 13% vs 2023 (€ 3,401) Favourable step	€ 2,685 Profit after taxes 2025: € 2,685 ▼ 30% vs 2024 (€ 3,858) Unfavourable step	▼ 30%
Equity	€ 89,401 Equity 2022: € 89,401 First fiscal year in the series	€ 92,802 Equity 2023: € 92,802 ▲ 4% vs 2022 (€ 89,401) Favourable step	€ 96,660 Equity 2024: € 96,660 ▲ 4% vs 2023 (€ 92,802) Favourable step	€ 99,345 Equity 2025: € 99,345 ▲ 3% vs 2024 (€ 96,660) Favourable step	▲ 3%
Total debts	€ 924,383 Total debts 2022: € 924,383 First fiscal year in the series	€ 849,540 Total debts 2023: € 849,540 ▼ 8% vs 2022 (€ 924,383) Favourable step	€ 1,067,696 Total debts 2024: € 1,067,696 ▲ 26% vs 2023 (€ 849,540) Unfavourable step	€ 1,212,490 Total debts 2025: € 1,212,490 ▲ 14% vs 2024 (€ 1,067,696) Unfavourable step	▲ 14%
Cash	€ 35,894 Cash 2022: € 35,894 First fiscal year in the series	€ 29,603 Cash 2023: € 29,603 ▼ 18% vs 2022 (€ 35,894) Unfavourable step	€ 1,794 Cash 2024: € 1,794 ▼ 94% vs 2023 (€ 29,603) Unfavourable step	€ 12,512 Cash 2025: € 12,512 ▲ € 10,718 vs 2024 (€ 1,794) Favourable step	▲ € 10,718
Land & buildings	€ 108,466 Land & buildings 2022: € 108,466 First fiscal year in the series	€ 95,306 Land & buildings 2023: € 95,306 ▼ 12% vs 2022 (€ 108,466) Unchanged	€ 105,649 Land & buildings 2024: € 105,649 ▲ 11% vs 2023 (€ 95,306) Unchanged	€ 90,240 Land & buildings 2025: € 90,240 ▼ 15% vs 2024 (€ 105,649) Unchanged	▼ 15%
Retained profit	€ 52,217 Retained profit 2022: € 52,217 First fiscal year in the series	€ 55,618 Retained profit 2023: € 55,618 ▲ 7% vs 2022 (€ 52,217) Favourable step	€ 59,476 Retained profit 2024: € 59,476 ▲ 7% vs 2023 (€ 55,618) Favourable step	€ 62,161 Retained profit 2025: € 62,161 ▲ 5% vs 2024 (€ 59,476) Favourable step	▲ 5%
Bank debt	€ 365,501 Bank debt 2022: € 365,501 First fiscal year in the series	€ 320,097 Bank debt 2023: € 320,097 ▼ 12% vs 2022 (€ 365,501) Favourable step	€ 241,860 Bank debt 2024: € 241,860 ▼ 24% vs 2023 (€ 320,097) Favourable step	€ 162,144 Bank debt 2025: € 162,144 ▼ 33% vs 2024 (€ 241,860) Favourable step	▼ 33%
Balance sheet total	€ 1,013,785 Balance sheet total 2022: € 1,013,785 First fiscal year in the series	€ 942,342 Balance sheet total 2023: € 942,342 ▼ 7% vs 2022 (€ 1,013,785) Unchanged	€ 1,164,356 Balance sheet total 2024: € 1,164,356 ▲ 24% vs 2023 (€ 942,342) Unchanged	€ 1,311,835 Balance sheet total 2025: € 1,311,835 ▲ 13% vs 2024 (€ 1,164,356) Unchanged	▲ 13%
Employees (FTE)	0.5 Employees (FTE) 2022: 0.5 First fiscal year in the series	0 Employees (FTE) 2023: 0 ▼ 0.5 vs 2022 (0.5) Unchanged	0 Employees (FTE) 2024: 0 Unchanged (0) Unchanged	0 Employees (FTE) 2025: 0 Unchanged (0) Unchanged

Key figures of GYNIM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to GYNIM?

What happened at GYNIM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 30, 2026 New annual accounts for financial year 2025: profit of € 2,685 (▼ 30% vs 2024). filed late Source: NBB ↗
2025 Dr. Ine Tavano BV became a director. NBB
2014 Dr. Sofie Pelckmans BV became a director. NBB
2014 Dr Jan Bosteels BV became a director. NBB
2014 Dokter Els Lannoey BV became a director. NBB
2014 Dokter Jan Baekelandt BV became a director. NBB
May 13, 1993 New establishment in Mechelen. KBO
Mar 30, 1993 Start of the company according to the CBE. KBO

In short

From € 0 profit in 2022 to € 2,685 profit in 2025.

Paid € 796 in corporate taxes since 2022.

Best year ever: 2024, with € 3,858 profit.

Original PDFs at the National Bank ↗

Management

Dr. Stefanie Verhelst 25%

DOKTER CARINE DE ROP 14.3%

Dr. Ine Tavano

The stake of Dr. Stefanie Verhelst, DOKTER CARINE DE ROP, Dr. Ine Tavano comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

GYNIM

Behind GYNIM are Dr. Sofie Pelckmans BV, Dr Jan Bosteels BV, Dr. Ine Tavano BV, Dr Nele Roggen BV, Dokter Els Lannoey BV and Dr Stefanie Verhelst BV. The shares are held by Dr. Stefanie Verhelst (25%), DOKTER CARINE DE ROP (14.3%) and Dr. Ine Tavano.

Directors

According to the 2025 annual accounts

Dr. Sofie Pelckmans BV

Director · represented by Sofie Pelckmans

since 2014

Dr Jan Bosteels BV

Director · represented by Jan Bosteels

since 2014

Dr. Ine Tavano BV

Director · represented by Ine Tavano

since 2025

Dr Nele Roggen BV

Director · represented by Nele Roggen

Dokter Els Lannoey BV

Director · represented by Els Lannoey

since 2014

Dr Stefanie Verhelst BV

Director · represented by Stefanie Verhelst

Dokter Jan Baekelandt BV

Director · represented by Jan Baekelandt

since 2014

Dokter Lynn Vercammen gynaec BV

Director · represented by Lynn Vercammen

Shareholders

Dr. Stefanie Verhelst

25%

DOKTER CARINE DE ROP

14.3%

Dr. Ine Tavano

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Schuttersvest 47

2800 Mechelen

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

AD Media Solutions

€ 2,716 gross margin · 2025

GYNIMMO

€ 27,672 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0449.783.951

VAT number

BE 0449.783.951

Registered office

Schuttersvest 47, 2800 Mechelen

Names & denominations

GYNIM

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

30 March 1993

Peppol

Active · Active since 4 Dec 2025

Activities · NACE

Activiteiten van medisch specialisten

Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗

GYNIM

Warning lights

Financials

What happened to GYNIM?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions